glp 1 drugs and pancreatitis GLP-1 Agonists Risk Concerns Raised Over Pancreatitis Risk

The GLP-1 response from dietary EVOO, while statistically significant, is part of the normal postprandial hormonal cascade -- a nudge, not a pharmacological override

For the humerus, the crude HR was 0.92 [0.681.24], and the adjusted HR was 0.91 [0.661.25] when comparing GLP-1 RAs with DPP-4is

This class of medications contains the popular semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon)

A clinical study involving 78 non-diabetic overweight/obese patients found that BN may be a more effective treatment option for overweight/obese Chinese than metformin (43)

Combination incretin therapies Next-generation pharmacological treatments for obesity include combinations of GLP-1 receptor agonists with other enteropancreatic hormones (such as GIP, glucagon and amylin)

These are generally transient and are mitigated by starting a low dose and titrating slowly